Ubrogepant vs. Triptan: New Migraine Treatment Insights

Research Summary

A recent study published in the journal Pain Management explored patient experiences when switching from one migraine treatment to another. The study, known as UNIVERSE II, surveyed adult users of the Migraine Buddy app who transitioned from an oral triptan to either another triptan or ubrogepant. Out of 694 participants, 211 were analyzed after screening. At the 30-day mark, those who switched to ubrogepant reported significantly higher satisfaction in managing migraine pain and alleviating bothersome symptoms compared to those who switched to another triptan. Additionally, 75.7% of the ubrogepant group preferred their new treatment over their previous triptan, demonstrating better outcomes in real-world settings.

Study Details

📄 Title: Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

👥 Research Team: Lipton RB et al.

📚 Published In: Pain Manag

📅 Publication Date: 2025 Nov 19

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.